WD-40 Company

WD-40 Company is one of the most distinctive single-product franchises in the public market — and one of the strangest investment cases. Founded in 1953 in San Diego, California by Norm Larsen at the Rocket Chemical Company, the blue-and-yellow aerosol can has become so synonymous with the lubricant category that the brand name functions as a verb. The company sells WD-40 Multi-Use (the original 1953 formula, still essentially unchanged), WD-40 Specialist, 3-IN-ONE, GT85, X-14, and a small line of cleaning products. Revenue 636 million USD in FY2025 (10.7 percent year-over-year), operating margin 16.3 percent, ROE 31.3 percent — the kind of returns-on-capital that quality investors pay premium multiples for.

At 201.37 USD the stock sits at the 33.4th percentile of its 52-week range (low 175.38, high 253.24), well below the 50-day moving average of 214.56 and the 200-day at 211.08. Trailing P/E 34.2, forward P/E 31.6, EV/EBITDA 24.5, P/B 10.1 — these are premium multiples for a 700-million-USD-revenue specialty chemical. The 1.95 percent dividend yield (3.92 USD annualized) with a 65 percent payout ratio is meaningful but not the focal point — WD-40 raised its dividend for the 16th consecutive year in 2025.

The story behind the drawdown: earnings growth was minus 31.5 percent in 2025 driven by petroleum-input-cost inflation (WD-40's core formula is petroleum-derived) and Asia-Pacific revenue softness. The combination compressed EPS from 8.60 USD trailing-2024 to 5.89 USD trailing-2025. Net income fell while revenue grew 10.7 percent — a clean margin-compression cycle, not a demand problem. This is the same cycle that hit consumer-staples-plus-specialty-chemicals peers in 2024 to 2025 (Church and Dwight, Energizer, Spectrum Brands).

Analyst consensus is limited (only 2 covering analysts — WD-40 is too small for most large sell-side desks) but the average price target is 249.50 USD with a 23.9 percent upside. The valuation-signal is flagged as overvalued by quantitative models, which is the consistent issue with WD-40 — it has traded at a 28 to 38x P/E for a decade because quality compounders rarely re-rate to cheap. The thesis here is buying a defensive single-product franchise at the lower third of its multi-year range, not buying it cheap on absolute valuation.

Institutional ownership at 95 percent of free-float is dominated by large-cap quality strategies — Vanguard (10.8 percent), BlackRock (8.3 percent), State Street (5.1 percent), American Funds Capital Research (4.6 percent). The active-fund side leans quality-growth and dividend-growth — T. Rowe Price, Wells Fargo, Diamond Hill — names that hold WD-40 as a 1 to 2 percent position for years rather than trading the cycle. There is no controlling family stake; the Larsen founder family exited management in the 1990s. The strategic-acquirer risk is low precisely because of the cult-brand premium — no specialty chemical buyer wants to pay 34x earnings for revenue synergies.

Short interest at 6.1 percent of float is the highest in WD-40's history — this is a quality-skeptic short trade, not a fundamental-distress short. The bear thesis is the valuation: at 31x forward earnings with mid-single-digit revenue growth and a near-mature core product line, what is the catalyst for re-rating? The short side is concentrated in deep-value and short-only funds; the long side is concentrated in 10-year-hold quality funds. The result is unusually low daily volatility (beta 0.32 — among the lowest in the small-mid-cap universe).

At 201.37 USD WDFC trades on 34.2x trailing P/E, 31.6x forward P/E, 4.3x sales, 10.1x book, and 24.5x EV/EBITDA. Free cash flow yield is 2.4 percent on equity. The valuation is rich by every traditional metric but historically consistent with the WD-40 multi-decade trading range. Beta of 0.32 confirms the low-volatility quality-defensive profile.

Three valuation paths. (1) Mean reversion to 200-day moving average of 211 USD without earnings improvement — 5 percent upside; (2) EPS recovery to 7 to 7.5 USD by end-2026 (Asia-Pacific margin recovery) at current 32x multiple — 224 to 240 USD per share, 11 to 19 percent upside; (3) Both EPS recovery to 8 USD in 2027 and multiple expansion to 34x (the long-term average) — 272 USD per share, 35 percent upside over 24 months. The 2-analyst consensus 249.50 USD is consistent with the middle scenario.

1. Q3 FY2026 (May 2026):

   Operating margin recovery toward 17 percent (versus 16.3 percent trailing) and Asia-Pacific organic revenue growth turning positive. The first clean quarter on both metrics confirms the margin reset is over.

2. Annual Investor Day (September 2026):

   WD-40 has not held a formal Investor Day since 2019. A 2026 capital-allocation-and-strategic-framework update would be a multi-year sentiment unlock.

3. Petroleum-input-cost normalization H2 2026:

   Brent crude staying in the 70 to 80 USD range supports gross-margin recovery. A drop below 70 USD would be a clean cost-side tailwind that pulls EPS forward.

WD-40 is the kind of defensive quality compounder that belongs in a portfolio sleeve for low-volatility income-and-growth — not a high-conviction value trade. The 33.4th-percentile entry combined with the 16-year dividend track record and the cult-brand pricing power makes this a reasonable patient buy. The risk is paying 32x forward earnings — if the margin recovery does not materialize on schedule, you wait through a flat 18 to 24 months.

I would size at 1 to 2 percent of portfolio for a 24 to 36 month horizon with a 175 USD stop-loss (at the 52-week low). Upside scenarios cluster at 240 to 275 USD; downside at 170 to 180. Asymmetry is approximately 2-to-1 favorable — less attractive than the cycle-bottom European industrials (Krones, Stevanato) but with a much lower-volatility risk profile. WD-40 is the trade you size large in a defensive bucket alongside Procter and Gamble or Church and Dwight, not a contrarian conviction position.